Bifidobacterium longum subsp. Longum C-5 with body weight regulation effect and application thereof

Abstract

The invention relates to bifidobacterium longum subsp. Longum C-5 with a body weight regulation effect and application of the bifidobacterium longum subsp. Longum C-5, the classification name of the bifidobacterium longum subsp. Longum C-5 is Bifidobacterium longum subsp. Longum, the preservation number of the bifidobacterium longum subsp. Longum is GDMCC No: 64542, and the preservation date of the bifidobacterium longum subsp. Longum C-5 is April 22, 2024. The strain can improve the effects of obesity, hyperlipidemia or inflammatory bowel disease and the like caused by high-fat diet by regulating blood sugar and blood fat levels, improving oxidative stress reaction, regulating adipose tissue metabolism, relieving liver injury or colon tissue inflammation and other action mechanisms, remarkably improve the symptoms of metabolic disorder, and can be used for treating obesity, hyperlipidemia, inflammatory bowel disease and the like. A coping strategy and a reference basis are provided for prevention and treatment of obesity.

Description

Technical Field

[0001] The invention belongs to the technical field of microbial culture, and relates to Bifidobacterium longum subspecies longum C-5 with weight regulating effect and application thereof. Background Art

[0002] Obesity is generally accompanied by symptoms such as lipid metabolism disorders, increased serum total cholesterol and triglyceride levels, etc. Among them, lipid metabolism disorders will further aggravate the body's inflammatory response, promote the secretion of inflammatory factors such as TNF-α and IL-6, and form a chronic low-grade inflammatory state. This state not only damages the metabolic balance, but may also have serious effects on the liver. Studies have shown that the liver, as a core organ of lipid metabolism, is susceptible to obesity and lipid metabolism disorders, and develops into fatty liver or non-alcoholic steatohepatitis and other diseases. These pathological changes not only aggravate the degree of metabolic disorders, but also further increase the risk of complications such as cardiovascular diseases.

[0003] Probiotics can improve the intestinal microecological balance of the host, improve the health level of the body, and affect the health and metabolism of the host by regulating the composition and abundance of intestinal microbiota, participating in immune regulation or improving gastrointestinal physiological functions. The diversity of intestinal flora in obese people is usually low, and the intestinal flora can affect and regulate body weight by regulating intestinal barrier function and reducing the secretion of inflammatory factors. Probiotics can regulate the composition of native symbiotic bacteria or directly colonize in the intestine to increase the abundance of intestinal microbiota with bile salt hydrolase ability, thereby increasing the concentration of unconjugated bile acids, affecting lipid metabolism, and alleviating various diseases caused by obesity. Therefore, how to provide a probiotic product with weight regulation effect, thereby alleviating related symptoms caused by obesity, hyperlipidemia or other inflammatory bowel diseases, so as to regulate the body's lipid metabolism and improve the body's health level has important significance and application value. Summary of the invention

[0004] In view of the shortcomings of the prior art, the object of the present invention is to provide a Bifidobacterium longum subspecies longum C-5 with weight regulation effect and its application.

[0005] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions: In a first aspect, the present invention provides a Bifidobacterium longum subspecies longum C-5 having a weight regulating effect, wherein the classification of the Bifidobacterium longum subspecies longum C-5 is named Bifidobacterium longum subsp. longum , the deposit number is GDMCC No: 64542, and the deposit date is April 22, 2024.

[0006] The present invention separates and preserves a new strain of Bifidobacterium longum subspecies long with weight regulating effect from the intestine of a healthy human body, and names it as Bifidobacterium longum subspecies longum C-5 strain. The strain has weight regulating effect, and can also regulate blood sugar and blood lipid levels, improve oxidative stress response, regulate adipose tissue metabolism, alleviate liver damage and colon tissue inflammation, etc. Therefore, the Bifidobacterium longum subspecies longum C-5 strain can be used to prepare a product with the effect of preventing, improving or treating hyperlipidemia or inflammatory bowel disease caused by a high-fat diet.

[0007] In a second aspect, the present invention provides a culture of Bifidobacterium longum subsp. longum C-5 as described in the first aspect, wherein the culture is prepared by the following method: Bifidobacterium longum subsp. longum C-5 is inoculated into a culture medium and cultured at 35-38° C. for 22-26 h.

[0008] Among them, the above-mentioned "35-38℃" can be, for example, 35℃, 35.5℃, 36℃, 36.5℃, 37℃, 37.5℃, 38℃, etc. Other specific point values ​​within the numerical range can be selected, and they will not be described one by one here.

[0009] The above-mentioned "22-26 h" can be, for example, 22 h, 22.5 h, 23 h, 23.5 h, 24 h, 24.5 h, 25 h, 25.5 h, 26 h, etc. Other specific point values ​​within the numerical range can be selected, and they will not be described one by one here.

[0010] In a third aspect, the present invention provides a probiotic with weight regulating effect, wherein the strain in the probiotic with weight regulating effect comprises the Bifidobacterium longum subspecies longum C-5 strain described in the first aspect.

[0011] Preferably, in the probiotic, the viable count of Bifidobacterium longum subspecies longum C-5 is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g, for example 1×10 9 CFU / mL (CFU / g), 2×10 9 CFU / mL (CFU / g), 5×10 9 CFU / mL (CFU / g), 8×10 9 CFU / mL (CFU / g), 1×10 10 CFU / mL (CFU / g), 5×10 10 CFU / mL (CFU / g), 1×10 11 CFU / mL (CFU / g), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0012] Preferably, the strains in the probiotics with weight regulation effect also include Lactobacillus gasseri Lactobacillus gasseri CKCC 1913, the deposit number is CGMCC No. 23175, and the deposit date is August 23, 2021.

[0013] The present invention also creatively discovered that the above-mentioned Lactobacillus gasseri Lactobacillus gasseri CKCC 1913 strain can bind to Bifidobacterium longum subsp. Bifidobacterium longum subsp. longum The C-5 strain was compounded to regulate body weight and improve body metabolism, and had better effects than a single bacterial agent or other compound methods, indicating that CKCC 1913 and C-5 had synergistic effects in regulating body weight, regulating blood sugar and blood lipids, and alleviating liver damage and colon tissue inflammation.

[0014] Preferably, the ratio of the number of viable bacteria of Bifidobacterium longum subspecies longum C-5 and CKCC 1913 is 1:10-10:1, for example, it can be 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 5:1, 6:1, 8:1, 10:1, etc. Other specific point values ​​within this numerical range can be selected, and they will not be described one by one here.

[0015] Preferably, the dosage form of the probiotic includes solution, lyophilized powder, capsule, tablet or granule.

[0016] Preferably, the probiotic is in the form of a solution, which is prepared by the following method: C-5 strain and CKCC1913 strain are inoculated into a culture medium respectively, activated and fermented in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, and resuspended with a solvent to obtain a C-5 bacterial suspension and a CKCC 1913 bacterial suspension, and the C-5 bacterial suspension and the CKCC 1913 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic; Preferably, the probiotic is in the form of a freeze-dried powder, which is prepared by the following method: The C-5 strain and the CKCC 1913 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain C-5 bacterial powder and CKCC 1913 bacterial powder; the C-5 bacterial powder and the CKCC 1913 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.

[0017] Preferably, the probiotic further comprises a protective agent; The protective agent includes any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

[0018] In a fourth aspect, the present invention provides a use of the Bifidobacterium longum subsp. longum C-5 as described in the first aspect, or the culture as described in the second aspect, or the probiotic as described in the third aspect in the preparation of a preparation for regulating blood sugar and blood lipid levels.

[0019] Compared with the prior art, the present invention has the following beneficial effects: The present invention separates and preserves a new strain of Bifidobacterium longum subspecies long with weight regulating effect from the intestine of a healthy human body, and names it as Bifidobacterium longum subspecies longum C-5 strain. The strain has weight regulating effect, and can also regulate blood sugar and blood lipid levels, improve oxidative stress response, regulate adipose tissue metabolism, alleviate liver damage and colon tissue inflammation, etc. Therefore, the Bifidobacterium longum subspecies longum C-5 strain can be used to prepare a product with the effect of preventing, improving or treating obesity, hyperlipidemia or inflammatory bowel disease caused by a high-fat diet.

[0020] The classification of the C-5 strain involved in the present invention is named Bifidobacterium longum subsp. longum The depository is Guangdong Microbiological Culture Collection Center, the deposit number is GDMCC No: 64542, the deposit date is April 22, 2024, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou; The CKCC 1913 strain involved in the present invention is classified as Lactobacillus gasseri Lactobacillus gasseri The depository is the General Microbiology Center of China Microorganism Culture Collection Administration, the deposit number is CGMCC No. 23175, the deposit date is August 23, 2021, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is a statistical graph of the body weight and inguinal fat content levels of mice in each group; Figure 2 It is the statistical result diagram of the levels of ALT, TC, GLU and NEFA in the serum of each group of mice; Figure 3 This is a statistical graph of the immune and oxidative stress levels of mice in each group; Figure 4 This is a statistical graph of the metabolic levels of adipose tissue in each group of mice; Figure 5This is the statistical result of the content levels of TC, TG, and FAS in the liver tissues of mice in each group; Figure 6 This is a statistical result chart of the short-chain fatty acid metabolism level in the feces of each group of mice; Figure 7 Figures are the results of pathological observation of liver, fat and colon tissue sections of each group of mice. DETAILED DESCRIPTION

[0022] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0023] ① The classification and nomenclature of the C-5 strains involved below are Bifidobacterium longum subsp. longum , the deposit number is GDMCC No: 64542; ② The CKCC 1913 strain involved below is named as Lactobacillus gasseri Lactobacillus gasseri , the deposit number is CGMCC No. 23175; ③ The CICC 24935 mentioned below is the Bifidobacterium longum subsp. longum CICC 24935 strain.

[0024] The culture medium and its formula involved below are: MRS liquid culture medium: beef extract 10.0 g, glucose 20.0 g, peptone 10.0 g, yeast extract 5.0 g, sodium chloride 5.0 g, diammonium hydrogen citrate 2.0 g, dipotassium hydrogen phosphate 2.0 g, magnesium sulfate 0.2 g, manganese sulfate 0.05 g, Tween-80 1.0 g, distilled water to 1000 mL, pH 6.2-6.4.

[0025] MRS solid medium: beef extract 10.0 g, glucose 20.0 g, peptone 10.0 g, yeast extract 5.0 g, sodium chloride 5.0 g, diammonium hydrogen citrate 2.0 g, dipotassium hydrogen phosphate 2.0 g, magnesium sulfate 0.2 g, manganese sulfate 0.05 g, Tween-80 1.0 g, 2% agar powder, distilled water to 1000 mL, pH 6.2-6.4.

[0026] The main ingredients of the following mouse feed formula are (mass percentage): Ordinary feed: corn 43.8%, second-grade flour 12%, wheat 17%, salted soybean meal 7%, Peruvian fish meal 4% and American chicken 5%; the main nutrients are: crude protein 19.54%, crude fat 4.43%, crude fiber 2.14%, calcium 1.36% and phosphorus 0.86%.

[0027] High-fat feed: maintenance base feed 48.1%, lard 15%, sucrose 20%, casein 10%, experimental animal premix 2%; the main nutrients are: protein 19.379%, fat 17.133%, crude fiber 3.321%, ash 5.3114%, calcium 1.26735%, phosphorus 0.82223%.

[0028] The C57BL / 6J male mice (8 weeks old) mentioned below were purchased from Yusibeifu (Beijing) Biotechnology Co., Ltd.

[0029] The preparation method of bacterial suspension and bacterial powder involved below is: after activating the strain, inoculate it into culture medium for cultivation to obtain culture solution; centrifuge the culture solution, resuspend the bacteria to obtain bacterial suspension, or further add protective agent for freeze drying to obtain freeze-dried bacterial powder product. Example 1

[0030] In this example, a strain of Bifidobacterium longum subspecies longum with weight regulation effect was isolated and screened, and the steps were as follows: Samples isolated from healthy human intestines were selected and diluted 10-fold using 0.9% saline solution for 3 times. The samples were spread on solid culture medium and cultured at 37°C for 48 hours. Colonies of different morphologies were picked out and purified by streaking on the surface of modified MRS solid culture medium. Single colonies were picked out and expanded using liquid culture medium at 37°C, and then preserved using 35% glycerol. Example 2

[0031] In this example, the strains screened in Example 1 were subjected to morphological identification and 16S rRNA molecular biological identification, and the steps were as follows: (1) Morphological identification: The strain was inoculated into MRS medium, cultured anaerobically at 37°C for 48 h, and then observed under a microscope. After smear and Gram staining, it was observed that the Gram staining was positive, the strain morphology was polymorphic, and it appeared as milky white, smooth, convex, and round colonies with neat edges on the MRS medium.

[0032] (2) 16S rRNA molecular biological identification: The strain stored at -80℃ was taken out and inoculated into a centrifuge tube containing 20mL MRS liquid medium at a ratio of 2% (v / v). After culturing at 37℃ for 24 hours, it was centrifuged and centrifuged at 8000 rpm for 10 minutes. The supernatant was removed and the bacteria were collected. The genome of the strain was extracted, and bacterial universal primers were added for PCR amplification. The amplified product was sent to a sequencing company for sequencing identification. The strain was sequenced and analyzed, and its 16S rRNA sequence was shown in SEQ ID No: 1. The sequence obtained by sequencing was compared with the nucleic acid sequence in GeneBank, and the results showed that the strain was Bifidobacterium longum subspecies longum.

[0033] SEQ ID No: 1:

[0034] Based on the results of 16S rRNA molecular biological identification and morphological identification in Example 2, it was confirmed that the strain belonged to Bifidobacterium longum subspecies longum and was named Bifidobacterium longum subspecies longum. Bifidobacterium longum subsp. longum C-5 strain.

[0035] Test Example 1 This test case explores the effects of the C-5 strain on various symptom indicators of obese mice. The specific steps are as follows: (1) Experimental animals: 96 8-week-old C57BL / 6J male mice were adaptively fed with normal feed in an animal room (room temperature: 22±2℃, humidity: 55%±10%, lighting 12 h) for one week (with free access to food and water).

[0036] (2) Grouping and intervention methods: After adaptive feeding, the mice were randomly divided into 8 groups: S1 group (C-5 bacterial suspension, high-fat diet), S2 group (CKCC 1913 bacterial suspension, high-fat diet), S3 group (C-5 bacterial suspension + CKCC 1913 bacterial suspension, live bacteria ratio of 10:1, high-fat diet), S4 group (C-5 bacterial suspension + CKCC 1913 bacterial suspension, live bacteria ratio of 1:1, high-fat diet), S5 group (C-5 bacterial suspension + CKCC 1913 bacterial suspension, live bacteria ratio of 1:10, high-fat diet), S6 group (CICC 24935 bacterial suspension + CKCC 1913 bacterial suspension, viable bacteria ratio of 10:1, high-fat diet), S7 group was the model group (sterile PBS solution, high-fat diet), S8 group was the blank group (sterile PBS solution, ordinary diet), each group had 12 mice, and the total viable bacteria in each group of S1-S6 was 10 9 CFU, each group was gavaged once a day, and the gavage volume of each bacterial suspension / sterile PBS solution was 0.2 mL; during the experiment, mice in each group had free access to food and water.

[0037] (3) The experiment lasted for a total of 6 weeks (including the first week of adaptive feeding and five weeks of gavage treatment). After the sixth week, the mice were killed and serum, adipose tissue, visceral tissue and other samples were collected for testing of relevant indicators.

[0038] (4) Detection and analysis of relevant indicators (a) Body weight and fat content The weight of each mouse in each group was measured in the sixth week of the experiment; the mice were killed after the last week of the experiment, and the inguinal fat was collected to detect the fat content. The statistical results of the mouse weight and inguinal fat content are as follows Figure 1 shown.

[0039] By giving mice a high-fat diet to induce hyperlipidemia, and then monitoring the weight changes and body fat content of the mice, the effect of probiotics on weight loss and body fat reduction can be intuitively evaluated. As shown in the figure, during the experiment, the weight of S7 (model group) mice was higher than that of S8 (control group). At the end of the experiment, the weight (184.44 g) and inguinal fat content (1.353 g) of S7 (model group) mice were significantly higher than those of S8 (control group) mice (146.95 g) and inguinal fat content (0.675 g). The inguinal fat proved that the obese mouse model was successfully established.

[0040] Both C-5 and CKCC 1913 bacterial suspensions can slow down the weight gain of obese mice after oral gavage, and C-5 bacterial suspension has the best slowing effect. In addition, it was unexpectedly discovered that when C-5 and CKCC 1913 bacteria are used in combination, the effect of slowing down the weight gain and body fat accumulation of obese mice is better.

[0041] (b) Blood sugar and lipid levels Mouse serum was collected and centrifuged at 571 g for 15 min at 4°C. The levels of alanine aminotransferase (ALT), total cholesterol (TC), glucose (GLU) and non-esterified fatty acids (NEFA) in serum were determined according to the instructions of the ELISA kit. The test results were as follows: Figure 2 shown.

[0042] Obesity caused by continuous intake of high-fat foods can lead to abnormalities in related blood indicators. These abnormal changes in blood lipid and blood sugar levels are directly related to the morbidity and mortality of coronary heart disease and other atherosclerotic diseases. Therefore, a long-term high-fat diet may disrupt the normal balance of blood components and increase the risk of cardiovascular disease.

[0043] From the statistical results in the figure, we can see that at the end of the experiment, the TC (16.92 mmol / L), ALT (154.1 U / L), NEFA (3.085 mmol / L) and GLU (8.437 mmol / L) levels of S7 (model group) mice were significantly higher than those of S8 (control group) mice; and after intervention with C-5 and CKCC 1913 bacterial suspensions, the blood lipid and blood sugar indicators can be effectively regulated and optimized, and the effect of C-5 bacterial suspension is the best. The levels of various indicators of S1 group mice showed a significant downward trend, and the effect was better than that of CICC 24935 bacteria; in addition, it was unexpectedly found that when C-5 and CKCC 1913 bacteria were used in combination, the relevant effect was better, which can effectively improve the relevant blood lipid and blood sugar indicators, thereby helping to reduce the incidence of coronary heart disease and other atherosclerotic diseases.

[0044] (c) Immune and oxidative stress levels Mouse serum was collected and centrifuged at 571 g for 15 min at 4°C. The level of tumor necrosis factor-α (TNF-α) in the serum was determined according to the instructions of the ELISA kit; Mouse liver tissue was collected and homogenized, and the levels of malondialdehyde (MDA) and superoxide dismutase (SOD) were detected according to the instructions of the kit. The results are as follows: Figure 3 shown.

[0045] Obesity caused by continuous intake of high-fat foods promotes adipose tissue peroxidation and inflammation, leading to increased levels of TNF-α in serum and MDA in the liver, and decreased activity of SOD in the liver, which not only aggravates insulin resistance, but also accelerates the occurrence of diseases such as atherosclerosis. After intervention with C-5 and CKCC 1913 bacterial suspension, the level of TNF-α inflammatory factor in serum decreased to varying degrees compared with the model group, and had a certain ability to inhibit lipid peroxidation. The MDA level was lower than that of the model group, and the SOD activity was higher than that of the model group. It can be seen that the two bacteria can inhibit liver peroxidation to varying degrees and relieve liver oxidative stress, and C-5 has the best effect; at the same time, when C-5 and CKCC 1913 are used in combination, the anti-inflammatory and antioxidant effects are better.

[0046] (d) Adipose tissue metabolic level White fat (epididymal fat, perirenal fat and inguinal fat) was collected, homogenized and ground, and the resistin and leptin indicators were tested according to the kit instructions. The results are as follows: Figure 4 shown.

[0047] Continuous high-fat diet usually leads to increased resistin levels, which may interfere with the insulin signaling pathway and reduce the sensitivity of mice to insulin, thereby causing metabolic problems such as hyperglycemia and insulin resistance. Leptin can improve insulin resistance and fat metabolism, thereby alleviating related symptoms.

[0048] As can be seen from the figure, the resistin (15.584 μg / L) in the adipose tissue of S7 (model group) mice was significantly higher than that of the control group (13.921 μg / L), and the leptin (6.297 μg / L) was significantly lower than that of the control group (7.662 μg / L); after intervention with C-5 and CKCC 1913 bacterial suspensions, the resistin and leptin in the adipose tissue decreased and increased to varying degrees, respectively, and the effect of C-5 was better. It can be seen that C-5 has a good effect in improving insulin resistance and fat metabolism, and has the effect of regulating adipose tissue metabolism in a high-fat diet; at the same time, when C-5 and CKCC 1913 were used in combination, they had a better effect.

[0049] (e) Level of liver damage Mouse liver tissue was collected and homogenized, and the levels of total cholesterol (TC), triglyceride (TG) and fatty acid synthase (FAS) were detected according to the instructions of the kit. The results are as follows Figure 5 shown.

[0050] Continuous high-fat diet can easily lead to the liver synthesizing large amounts of cholesterol. Excessive accumulation of cholesterol in the liver can lead to fatty liver, blood viscosity, atherosclerosis and other symptoms. Fatty acid synthase (FAS) is synthesized in the liver and can serve as a potential therapeutic target for fatty liver and dyslipidemia.

[0051] After oral administration of C-5 and CKCC 1913, the levels of three liver-related indicators decreased to varying degrees, and C-5 had the best effect, indicating that C-5 has the effect of improving blood lipid levels and liver health, and helps to reduce the related metabolic burden; when C-5 and CKCC 1913 are used in combination, they have a better effect.

[0052] (f) Short-chain fatty acid metabolism level In the sixth week of the experiment, the feces of mice in each group were collected and freeze-dried, and short-chain fatty acids (SCFAs) were extracted. The levels of short-chain fatty acids (propionic acid, valeric acid, and isobutyric acid) in the fecal samples of each group were quantitatively analyzed using gas chromatography. The results are as follows: Figure 6 shown.

[0053] Short-chain fatty acids (propionic acid, valeric acid, isobutyric acid) play an important role in intestinal microbial metabolism and metabolic health regulation, and can play anti-inflammatory, antibacterial and intestinal integrity regulation roles. After oral administration of C-5 and CKCC 1913, the levels of the three short-chain fatty acids in the feces of mice increased to varying degrees, and C-5 had the best effect, indicating that C-5 has the ability to regulate short-chain fatty acid metabolism under a high-fat diet, which helps to improve overall metabolic health; further, when C-5 and CKCC 1913 are used in combination, the relevant regulatory ability is better.

[0054] (g) Histopathological observation of liver, fat and colon sections Liver, fat, and colon tissues from groups S1, S7, and S8 were collected for H&E and Oil Red O staining sections, and pathological changes in tissue or cell morphology in the sections were observed under an optical microscope. Figure 7 shown.

[0055] The staining results in the figure show that in the liver staining model, compared with S7 (model group), the positive area of ​​S1 group (C-5 intervention group) was significantly reduced, indicating that C-5 has a good protective effect on liver damage caused by a high-fat diet and reduces the degree of pathological damage to the liver; in the fat section observation, the fat of S8 (control group) is dense and uniform, the fat area of ​​S7 (model group) is larger, and the fat area of ​​S1 group (C-5 intervention group) shows a shrinking trend, indicating that C-5 helps reduce fat accumulation and has a certain improvement effect on obesity or fatty liver.

[0056] In S7 (model group), the mucosal layer of the intestinal tissue formed obvious folds, and the mucosal epithelium was composed of a single layer of columnar epithelium and goblet cells. The lamina propria contained a large number of densely arranged intestinal glands, containing a large number of goblet cells and a small number of columnar cells. The muscularis mucosa separated the lamina propria from the submucosa, which was loose connective tissue with focal aggregation of lymphocytes. In contrast, the intestinal tissue of the S1 group (C-5 intervention group) did not show the above abnormal manifestations, showing a significant improvement effect. It can be seen that C-5 intervention treatment has a positive effect on maintaining intestinal health and reducing inflammatory response.

[0057] In summary, the present invention has isolated and preserved a new strain of Bifidobacterium longum subspecies longum with weight regulation effect, which is named Bifidobacterium longum subspecies longum Bifidobacterium longum subsp. longum The C-5 strain has the effect of regulating body weight, and can also regulate blood sugar and blood lipid levels, improve oxidative stress response, regulate adipose tissue metabolism, relieve liver damage and colon tissue inflammation, etc. Therefore, this Bifidobacterium longum subspecies C-5 strain can be used to prepare a product that has the effect of preventing, improving or treating obesity, hyperlipidemia or inflammatory bowel disease caused by a high-fat diet.

[0058] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0059] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0060] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A Bifidobacterium longum subspecies longum C-5 having a weight regulating effect, characterized in that: The classification of the Bifidobacterium longum subspecies longum C-5 is named Bifidobacterium longum subsp. longum , the deposit number is GDMCC No:64542, and the deposit date is April 22, 2024.

2. A culture of Bifidobacterium longum subspecies longum C-5 as claimed in claim 1, characterized in that The culture was prepared by the following method: Bifidobacterium longum subspecies longum C-5 was inoculated into a culture medium and cultured at 35-38° C. for 22-26 h.

3. A probiotic agent with weight regulation effect, characterized in that: The strain in the probiotic with weight regulation effect includes the Bifidobacterium longum subsp. longum C-5 strain as claimed in claim 1.

4. The probiotic agent with weight regulation effect as claimed in claim 3, characterized in that: In the probiotic, the viable count of the Bifidobacterium longum subspecies longum C-5 is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g.

5. The probiotic agent with weight regulation effect as claimed in claim 3, characterized in that: The strains in the probiotics with weight regulation effects also include Lactobacillus gasseri Lactobacillus gasseri CKCC 1913, the deposit number is CGMCC No. 23175, and the deposit date is August 23, 2021.

6. The probiotic agent with weight regulation effect as claimed in claim 5, characterized in that: The ratio of the viable counts of Bifidobacterium longum subspecies longum C-5 to Lactobacillus gasseri CKCC 1913 is 1:10-10:

1.

7. The probiotic agent with weight regulation effect as claimed in claim 3, characterized in that: The dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule.

8. The probiotic agent with weight regulation effect according to claim 5, characterized in that: The dosage form of the probiotic is a solution, which is prepared by the following method: The C-5 strain and the CKCC 1913 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broths are centrifuged respectively, and resuspended with a solvent to obtain a C-5 bacterial suspension and a CKCC 1913 bacterial suspension; the C-5 bacterial suspension and the CKCC 1913 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent; Alternatively, the probiotic is in the form of a freeze-dried powder, which is prepared by the following method: The C-5 strain and the CKCC 1913 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a protective agent and freeze-dried to obtain C-5 bacterial powder and CKCC 1913 bacterial powder; the C-5 bacterial powder and the CKCC 1913 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.

9. The probiotic agent with weight regulation effect as claimed in claim 3, characterized in that: The probiotics also include a protective agent; The protective agent includes any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

10. Use of the Bifidobacterium longum subsp. longum C-5 according to claim 1 or the culture according to claim 2 or the probiotic according to any one of claims 3 to 9 in the preparation of a preparation for regulating blood sugar and blood lipid levels.

Images